Navigation Links
STERIS Corporation Declares Regular Quarterly Dividend
Date:4/23/2008

MENTOR, Ohio, April 23 /PRNewswire-FirstCall/ -- STERIS Corporation (NYSE: STE) today announced that its Board of Directors has authorized a regular quarterly dividend in the amount of $0.06 per common share. The dividend is payable June 11, 2008 to shareholders of record at the close of business on May 14, 2008.

About STERIS

The mission of STERIS Corporation is to provide a healthier today and safer tomorrow through knowledgeable people and innovative infection prevention, decontamination and health science technologies, products and services. The Company's more than 5,000 dedicated employees around the world work together to supply a broad array of solutions by offering a combination of equipment, consumables and services to healthcare, pharmaceutical, industrial and government customers. The Company is listed on the New York Stock Exchange under the symbol STE. For more information, visit http://www.steris.com .

This news release may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to the Company or its industry that are intended to qualify for the protections afforded "forward-looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of this report, and may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "targets," "forecasts," "confidence," and "seeks," or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, disruption of production or supplies, changes in market conditions, political events, pending or future claims or litigation, competitive factors, technology advances, and changes in government regulations or the application or interpretation thereof. Other risk factors are described in the Company's Form 10-K and other securities filings. Many of these important factors are outside STERIS's control. No assurances can be provided as to any future dividend payment or other financial results. Unless legally required, the Company does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, (a) the potential for increased pressure on pricing that leads to erosion of profit margins, (b) the possibility that market demand will not develop for new technologies, products or applications, or the Company's business initiatives will take longer, cost more or produce lower benefits than anticipated, (c) the possibility that application of or compliance with laws, court rulings, regulations, certifications or other requirements or standards may delay or prevent new product introductions, affect the production and marketing of existing products, or otherwise affect Company performance, results, or value, (d) the potential of international unrest or effects of fluctuations in currencies, tax assessments or rates, raw material costs, benefit or retirement plan costs, or other regulatory compliance costs, (e) the possibility of reduced demand, or reductions in the rate of growth in demand, for the Company's products and services, and (f) the possibility that anticipated cost savings may not be achieved, or that transition, labor, competition, timing, execution, regulatory, governmental, or other issues or risks associated with the matters described in this release may adversely impact Company performance, results, or value.


'/>"/>
SOURCE STERIS Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. STERIS Corporation Names Michael J. Tokich Chief Financial Officer
2. STERIS Corporation Announces New $300 Million Share Repurchase Authorization
3. STERIS Corporation Promotes Timothy L. Chapman to Group President of Healthcare
4. STERIS Corporation Announces Fiscal 2008 Third Quarter Results
5. STERIS Corporation Declares Regular Quarterly Dividend
6. STERIS Corporation Announces Date of Fiscal 2008 Third Quarter Earnings Release and Conference Call
7. STERIS Corporation Announces Fiscal 2008 Second Quarter Results
8. STERIS Corporation Announces Date of Fiscal 2008 Second Quarter Earnings Release and Conference Call
9. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
10. Webcast Alert: Heska Corporations Annual Meeting of Stockholders Webcast
11. Vystar Corporation and Revertex Malaysia Sign Vytex(TM) NRL Production Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... , ... The Journal of Pain Research has seen a significant ... data taken from the Scopus database (Elsevier B.V.) and is a measure of a ... journal over a three year period and also the importance of the journals where ...
(Date:2/11/2016)... Petersburg, FL (PRWEB) , ... February 11, 2016 ... ... providers and advocates will discuss how to improve care by making data on ... pediatric heart disease. The Summit on Transparency and Public Reporting of Pediatric and ...
(Date:2/11/2016)... ... February 11, 2016 , ... The Commission for Case Manager ... of Commissioners. Individuals interested in volunteer board service are encouraged to apply. The ... settings and across allied health to contribute to its mission and vision. The ...
(Date:2/11/2016)... ... February 11, 2016 , ... Colorado spine surgeon, Donald Corenman, ... 334 spine surgeons to know in 2016 . The list consists of spine surgeons ... surgery. , Dr. Corenman understands the importance of clinical excellence; he has been ...
(Date:2/11/2016)... DC (PRWEB) , ... February 11, 2016 , ... The ... is based on evaluation of DataPoint’s team dedication and commitment to the ... companies comprising the annual list. The panel’s goal is to recognize and promote technology ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... YORK , Feb. 11, 2016 ... - Companion Diagnostics in Personalized Medicine and Cancer Therapy. ... - High-Growth Diagnostic Testing Markets. - Key ... Testing. - Molecular Diagnostics in Genetic Testing. ... Molecular Diagnostics Markets. - Over-the-Counter Diagnostic Products World ...
(Date:2/11/2016)... 11, 2016 The primary goal of this ... patterns on the usage of liquid biopsy. Key information ... - Timeframe of liquid biopsy adoption amidst future ... Evs—by organization type - Sample inflow to conduct liquid ... stool, serum, and so on. - Correlation analysis of ...
(Date:2/11/2016)... 2016 Stem cells are primitive cells found ... and the capacity to differentiate into mature cell types ... the first mouse embryonic stem cells were derived from ... that the first culturing of embryonic stem cells from ... produced until 2006 As a result of these discoveries, ...
Breaking Medicine Technology: